Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: Long-term durability with Prostcare

Yuh Shyan Tsai, Johnny Shinn Nan Lin, Yat Ching Tong, Tzong Shin Tzai, Wen Horng Yang, Chien Cheng Chang, Hong Lin Cheng, Yung Ming Lin, Yeong Chin Jou

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To evaluate the long-term durability of transurethral microwave thermotherapy (TUMT) with Prostcare for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 to July 1994, a total of 65 patients with symptomatic BPH who underwent TUMT using the Prostcare apparatus (Bruker Spectospin, Wissembourg, France) with low-energy protocol (maximal power 52 W) were enrolled into a short-term evaluation. Subsequent follow-up information was collected in July 1999. If patients had had any further therapy for BPH, the date of retreatment was considered as an endpoint of TUMT efficacy. If no further therapy for BPH had been needed, they were re-assessed for overall satisfaction. Results: The median follow-up period was 49 months. Twenty patients were excluded for various reasons, including 17 with loss of follow-up and 3 with new diseases that could affect the voiding status. Thirty-eight (84.4%) of 45 valuable patients had received further therapy for BPH, including medication (n = 21, 46.7%), and endoscopic surgery (n = 17, 37.7%). The times to pharmacologic or endoscopic retreatment after TUMT were 8.9 ± 11.1 and 23.0 ± 14.4 months, respectively (p = 0.0003, log rank test). Only 7 (15.5%) patients had no further treatment, with 3 having satisfactory improvements, but 4 feel dissatisfied yet not needing any further therapy. In addition, 2 patients complained of erectile dysfunction after TUMT and 1 was diagnosed with prostate cancer 50 months after TUMT. In addition, there was no significant difference for all baseline values among three groups with no retreatment or retreatment with medication or endoscopic surgery. Conclusion: At the 5-year follow-up, the long-term durability of low-energy TUMT with Prostcare is only exhibited in a few patients and the overall retreatment rate was 84.4%. Thus, patient should be informed of the high probability of supplementary treatment after TUMT.

Original languageEnglish
Pages (from-to)688-694
Number of pages7
JournalEuropean Urology
Volume39
Issue number6
DOIs
Publication statusPublished - 2001 Aug 6

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Retreatment
Therapeutics
Erectile Dysfunction
France
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Tsai, Yuh Shyan ; Lin, Johnny Shinn Nan ; Tong, Yat Ching ; Tzai, Tzong Shin ; Yang, Wen Horng ; Chang, Chien Cheng ; Cheng, Hong Lin ; Lin, Yung Ming ; Jou, Yeong Chin. / Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia : Long-term durability with Prostcare. In: European Urology. 2001 ; Vol. 39, No. 6. pp. 688-694.
@article{91104115464746b5961a8c98e7838777,
title = "Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia: Long-term durability with Prostcare",
abstract = "Objective: To evaluate the long-term durability of transurethral microwave thermotherapy (TUMT) with Prostcare for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 to July 1994, a total of 65 patients with symptomatic BPH who underwent TUMT using the Prostcare apparatus (Bruker Spectospin, Wissembourg, France) with low-energy protocol (maximal power 52 W) were enrolled into a short-term evaluation. Subsequent follow-up information was collected in July 1999. If patients had had any further therapy for BPH, the date of retreatment was considered as an endpoint of TUMT efficacy. If no further therapy for BPH had been needed, they were re-assessed for overall satisfaction. Results: The median follow-up period was 49 months. Twenty patients were excluded for various reasons, including 17 with loss of follow-up and 3 with new diseases that could affect the voiding status. Thirty-eight (84.4{\%}) of 45 valuable patients had received further therapy for BPH, including medication (n = 21, 46.7{\%}), and endoscopic surgery (n = 17, 37.7{\%}). The times to pharmacologic or endoscopic retreatment after TUMT were 8.9 ± 11.1 and 23.0 ± 14.4 months, respectively (p = 0.0003, log rank test). Only 7 (15.5{\%}) patients had no further treatment, with 3 having satisfactory improvements, but 4 feel dissatisfied yet not needing any further therapy. In addition, 2 patients complained of erectile dysfunction after TUMT and 1 was diagnosed with prostate cancer 50 months after TUMT. In addition, there was no significant difference for all baseline values among three groups with no retreatment or retreatment with medication or endoscopic surgery. Conclusion: At the 5-year follow-up, the long-term durability of low-energy TUMT with Prostcare is only exhibited in a few patients and the overall retreatment rate was 84.4{\%}. Thus, patient should be informed of the high probability of supplementary treatment after TUMT.",
author = "Tsai, {Yuh Shyan} and Lin, {Johnny Shinn Nan} and Tong, {Yat Ching} and Tzai, {Tzong Shin} and Yang, {Wen Horng} and Chang, {Chien Cheng} and Cheng, {Hong Lin} and Lin, {Yung Ming} and Jou, {Yeong Chin}",
year = "2001",
month = "8",
day = "6",
doi = "10.1159/000052528",
language = "English",
volume = "39",
pages = "688--694",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia : Long-term durability with Prostcare. / Tsai, Yuh Shyan; Lin, Johnny Shinn Nan; Tong, Yat Ching; Tzai, Tzong Shin; Yang, Wen Horng; Chang, Chien Cheng; Cheng, Hong Lin; Lin, Yung Ming; Jou, Yeong Chin.

In: European Urology, Vol. 39, No. 6, 06.08.2001, p. 688-694.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transurethral microwave thermotherapy for symptomatic benign prostatic hyperplasia

T2 - Long-term durability with Prostcare

AU - Tsai, Yuh Shyan

AU - Lin, Johnny Shinn Nan

AU - Tong, Yat Ching

AU - Tzai, Tzong Shin

AU - Yang, Wen Horng

AU - Chang, Chien Cheng

AU - Cheng, Hong Lin

AU - Lin, Yung Ming

AU - Jou, Yeong Chin

PY - 2001/8/6

Y1 - 2001/8/6

N2 - Objective: To evaluate the long-term durability of transurethral microwave thermotherapy (TUMT) with Prostcare for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 to July 1994, a total of 65 patients with symptomatic BPH who underwent TUMT using the Prostcare apparatus (Bruker Spectospin, Wissembourg, France) with low-energy protocol (maximal power 52 W) were enrolled into a short-term evaluation. Subsequent follow-up information was collected in July 1999. If patients had had any further therapy for BPH, the date of retreatment was considered as an endpoint of TUMT efficacy. If no further therapy for BPH had been needed, they were re-assessed for overall satisfaction. Results: The median follow-up period was 49 months. Twenty patients were excluded for various reasons, including 17 with loss of follow-up and 3 with new diseases that could affect the voiding status. Thirty-eight (84.4%) of 45 valuable patients had received further therapy for BPH, including medication (n = 21, 46.7%), and endoscopic surgery (n = 17, 37.7%). The times to pharmacologic or endoscopic retreatment after TUMT were 8.9 ± 11.1 and 23.0 ± 14.4 months, respectively (p = 0.0003, log rank test). Only 7 (15.5%) patients had no further treatment, with 3 having satisfactory improvements, but 4 feel dissatisfied yet not needing any further therapy. In addition, 2 patients complained of erectile dysfunction after TUMT and 1 was diagnosed with prostate cancer 50 months after TUMT. In addition, there was no significant difference for all baseline values among three groups with no retreatment or retreatment with medication or endoscopic surgery. Conclusion: At the 5-year follow-up, the long-term durability of low-energy TUMT with Prostcare is only exhibited in a few patients and the overall retreatment rate was 84.4%. Thus, patient should be informed of the high probability of supplementary treatment after TUMT.

AB - Objective: To evaluate the long-term durability of transurethral microwave thermotherapy (TUMT) with Prostcare for symptomatic benign prostatic hyperplasia (BPH). Patients and Methods: From August 1993 to July 1994, a total of 65 patients with symptomatic BPH who underwent TUMT using the Prostcare apparatus (Bruker Spectospin, Wissembourg, France) with low-energy protocol (maximal power 52 W) were enrolled into a short-term evaluation. Subsequent follow-up information was collected in July 1999. If patients had had any further therapy for BPH, the date of retreatment was considered as an endpoint of TUMT efficacy. If no further therapy for BPH had been needed, they were re-assessed for overall satisfaction. Results: The median follow-up period was 49 months. Twenty patients were excluded for various reasons, including 17 with loss of follow-up and 3 with new diseases that could affect the voiding status. Thirty-eight (84.4%) of 45 valuable patients had received further therapy for BPH, including medication (n = 21, 46.7%), and endoscopic surgery (n = 17, 37.7%). The times to pharmacologic or endoscopic retreatment after TUMT were 8.9 ± 11.1 and 23.0 ± 14.4 months, respectively (p = 0.0003, log rank test). Only 7 (15.5%) patients had no further treatment, with 3 having satisfactory improvements, but 4 feel dissatisfied yet not needing any further therapy. In addition, 2 patients complained of erectile dysfunction after TUMT and 1 was diagnosed with prostate cancer 50 months after TUMT. In addition, there was no significant difference for all baseline values among three groups with no retreatment or retreatment with medication or endoscopic surgery. Conclusion: At the 5-year follow-up, the long-term durability of low-energy TUMT with Prostcare is only exhibited in a few patients and the overall retreatment rate was 84.4%. Thus, patient should be informed of the high probability of supplementary treatment after TUMT.

UR - http://www.scopus.com/inward/record.url?scp=17844368344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844368344&partnerID=8YFLogxK

U2 - 10.1159/000052528

DO - 10.1159/000052528

M3 - Article

C2 - 11464059

AN - SCOPUS:17844368344

VL - 39

SP - 688

EP - 694

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -